ScinoPharm to provide topiramate API for Vivus anti-obesity drug
The FDA-approved Qsymia is used as a treatment for chronic weight management in adults who are obese or overweight with a weight-related comorbidity. Clinical studies have showed that
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The expanded alliance comprises three components co-development of present and future formulations of migalastat HCl for Fabry disease, commercialisation arrangements for all future Fabry products and increased GSK